Drug intelligence / Profile preview

foscelantan

Development stage: Phase 3
Lead developer: Research Institute for Physical and Chemical Problems of the Belarusian State University
Modality: Implantable Devices → Device-based Delivery → Drug Delivery Systems
Administration: Topical

Overview

Foscelantan is an innovative medicinal product being developed by Belarusian State University (BSU) to accelerate the regeneration of damaged tissues. It is designed as a bioabsorbable plate for wound healing, particularly for treating purulent-inflammatory processes of the skin and soft tissues.

Brand names: Foscelantan

Beyond the preview

Go deeper on foscelantan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on foscelantan.

Explore the full profile